Pfizer (NYSE:PFE) Stock Price Down 1.2% – Time to Sell?

Shares of Pfizer Inc. (NYSE:PFE) were down 1.2% on Monday . The company traded as low as $24.72 and last traded at $24.7470. 36,778,430 shares traded hands during mid-day trading, a decline of 14% from the average daily volume of 42,647,055 shares. The stock had previously closed at $25.05.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on PFE shares. Morgan Stanley upped their price objective on Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. JPMorgan Chase & Co. decreased their target price on shares of Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research note on Wednesday, July 8th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. Citigroup increased their price target on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Finally, Guggenheim decreased their price objective on shares of Pfizer from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Pfizer has an average rating of “Hold” and a consensus price target of $28.50.

Pfizer Stock Performance

The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The stock has a 50-day moving average price of $25.21 and a 200-day moving average price of $26.18. The company has a market capitalization of $141.04 billion, a price-to-earnings ratio of 18.89 and a beta of 0.35.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period in the previous year, the firm earned $0.92 EPS. The firm’s revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Friday, July 24th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date is Friday, July 24th. Pfizer’s payout ratio is currently 131.30%.

Institutional Trading of Pfizer

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Penn Davis Mcfarland Inc. increased its stake in Pfizer by 50.9% during the 4th quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock worth $4,266,000 after acquiring an additional 57,777 shares during the period. Vanguard Group Inc. lifted its position in shares of Pfizer by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 541,346,182 shares of the biopharmaceutical company’s stock valued at $13,479,520,000 after acquiring an additional 7,031,162 shares during the period. KBC Group NV lifted its position in shares of Pfizer by 8.3% during the 4th quarter. KBC Group NV now owns 9,193,713 shares of the biopharmaceutical company’s stock valued at $228,924,000 after acquiring an additional 706,426 shares during the period. Pensionfund Sabic acquired a new stake in shares of Pfizer during the 4th quarter worth $1,863,000. Finally, North Dakota State Investment Board bought a new position in shares of Pfizer in the fourth quarter worth $5,348,000. Institutional investors own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.